HK Stock Price Fluctuated | Biomedical stocks show collective strength, with BRII-B (02137) briefly surging over 15%. Institutions indicate that innovative drugs are expected to experience a high boom.

In the early morning trading session, the biopharmaceutical stocks collectively strengthened. As of the time of writing, BRII-B (02137) rose by 12.18% to HKD 2.67; EVEREST MED-B (01952) rose by 11.57% to HKD 27; Hangzhou Tigermed Consulting (03347) rose by 8.07% to HKD 43.5; CANSINOBIO (06185) rose by 8.19% to HKD 25.75; REMEGEN (09995) rose by 7.73% to HKD 41.8. On the news front, Novo Nordisk announced on Tuesday that the GLP-1 drug Ozempic has achieved the predetermined endpoint for the early termination of a phase III clinical trial aimed at preventing the progression of kidney damage in type 2 diabetes and chronic kidney disease patients. In addition, data released by the Chinese Center for Disease Control and Prevention (CDC) shows that in September, there were 45 newly reported deaths due to COVID-19 and 398 newly reported severe cases. Guotai Junan pointed out that the policy environment for the pharmaceutical industry is showing signs of improvement, and academic activities are gradually resuming. The new round of negotiations on medical insurance is approaching, and the payment environment is expected to see marginal improvement. Domestic innovative drugs are gradually going abroad, and the progress of internationalization is encouraging. The rating of holding innovative drug industry is maintained. Attention should be paid to multiple catalysts in the innovative drug industry. Minsheng Securities stated that the significant increase in GLP-1 drug sales is driving the high prosperity of the upstream supply chain, and the financing and investment in overseas biopharmaceuticals are expected to continue to improve.